ClinicalTrials.gg
CompletedNCT01718691Updated Apr 27, 2016Results posted

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

A Phase 2 interventional study of SyB L-0501 and rituximab in Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated, sponsored by SymBio Pharmaceuticals. Completed at 14 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by SymBio Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing bendamustine in Lymphoma, Mantle-Cell — 2 open to participants now, 7 under way, 1 of them phase 3. bendamustine · Lymphoma, Mantle-Cell.

Enrollment
4th of 32
70 · median 42
Started
2011
with 1 other
Phase 2
16 of 32
1 open now
Registered
20th of 32
by date
Lead sponsor
4 of 32
SymBio Pharmaceuticals

Among the 32 studies testing bendamustine in Lymphoma, Mantle-Cell, this one is the 4th largest by enrollment, is one of 2 that started in 2011, is one of 16 in phase 2, and was the 20th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

2 of the 32 studies testing bendamustine in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing bendamustine in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of SyB L-0501 (two-day consecutive 90 mg/m2/day IV drip infusions) in combination with rituximab (375 mg/m2 IV drip infusion) on untreated, low-grade B cell non-Hodgkin's lymphoma and mantle cell lymphoma where hematopoietic stem cell transplantation is not indicated.

03

Conditions studied

  • Low-grade B Cell Non-Hodgkin's Lymphoma
  • Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are histopathologically confirmed to have the following cluster of differentiation 20 (CD20) positive low-grade B cell non-Hodgkin's lymphoma or mantle cell lymphoma by lymph node or evaluable tissue biopsy within 6 months before the registration WHO Classification of Tumors (fourth edition):

    • Small lymphocytic lymphoma
    • Splenic marginal zone B-cell lymphoma
    • Lymphoplasmacytic lymphoma
    • Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
    • Nodal marginal zone B-cell lymphoma
    • Follicular lymphoma (Grade 1, 2, 3a)
    • Mantle cell lymphoma
  2. Patients with a ( > 1.5 cm in major axis on CT)
  3. Patients without a medical history
  4. Patients with at least 1 of the following clinical symptoms or signs (excluding mantle cell lymphoma):

    • Bulky disease measuring > 7 cm in major axis on CT (excluding spleen)
    • B symptoms

      1. Fever exceeding 38.0ºC of unknown cause
      2. Night sweats
      3. Weight decrease exceeding 10% within 6 months before patient registration
    • Elevated serum LDH or beta 2 microglobulin
    • Three or more regional lymph nodes of > 3 cm in major axis on CT
    • Symptomatic splenomegaly
    • Intracranial pressure
    • Pleural effusion/ascites retention
  5. Patients expected to live for at least 3 months
  6. Patients aged between 20 and 79 years (at the time of registration)
  7. Patients whose (ECOG) performance status (P.S.) is 0~2
  8. Patients with adequately maintained major organ function (bone marrow, heart, lungs, liver, kidneys)

    • : not less than 1,500 /mm3
    • count: not less than 75,000 /mm3
    • (AST)[Glutamic oxaloacetic transaminase (GOT)]: not more than 3 times the standard upper limit for the site
    • Alanine aminotransferase (ALT)[Glutamic pyruvic transaminase (GPT)]: not more than 3 times the standard upper limit for the site
    • Total : not more than 1.5 times the standard upper limit for the site
    • Serum creatinine: not more than 1.5 times the standard upper limit for the site
    • Arterial partial pressure of oxygen (PaO2): not less than 65 mmHg
    • shows no abnormal findings that require treatment
    • Echocardiogram of (LVEF): not less than 55%
  9. Patients whose has been obtained in person

Exclusion criteria

Exclusion Criteria:

Patients who fall under any one of the following criteria are to be excluded

  1. Patients whose transformation has been confirmed histopathologically
  2. Mantle cell lymphoma patients aged 65 years or younger
  3. Patients who were administered or received transfusion of cytokine formulations such as G-CSF (granulocyte colony stimulating factor) and erythropoietin within 14 days before pre-registration test
  4. Patients with severe active infectious disorders (receiving antibiotics, antifungals, or antivirus IV injection)
  5. Patients with serious complications (such as hepatic or renal failure)
  6. Patients with severe complications of cardiac disease (examples: myocardial infarction, ischemic heart disease) or its previous history within 2 years before patient registration, and patients with arrhythmia requiring a treatment
  7. Patients with serious gastrointestinal conditions (persistent or severe nausea/vomiting or diarrhea)
  8. Patients who are positive for surface (HBs) antigen, virus (HCV) antibody or antibody [if HBs or hepatitis B core (HBc) positive, patients whose hepatitis B virus (HBV)-DNA test results indicate positive]
  9. Patients with serious bleeding tendencies [such as disseminated intravascular coagulation (DIC)]
  10. Patients having or suspected of having symptoms indicative of the central nervous system (CNS) involvement
  11. Patients with interstitial pneumonitis, pulmonary fibrosis, pulmonary emphysema complications requiring treatment or its medical history.
  12. Patients with active multiple primary cancer
  13. Patients who received chemotherapy, radiotherapy, antibody therapy and antitumor therapy in the past
  14. Patients with complications or medical history of haemolytic anaemia
  15. Patients who were administered investigative or unapproved drugs within 3 months before patient registration
  16. Patients with addiction to drugs or narcotics, or alcoholism
  17. Patients who have previously received hematopoietic stem cell transplantation
  18. Patients who are or may be pregnant, lactating patients
  19. Patients, whether male or female, who do not agree to use
  20. Patients otherwise judged by the investigator or the sub-investigator to be unsuitable for inclusion in the study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    SyB L-0501+rituximab

    Drug: SyB L-0501 · Drug: rituximab

Interventions

  • A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.

  • A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.

06

What researchers measure

Primary outcomes

  1. Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)

    The criteria for CR and CRu based on IWRC are shown below. CR: Fulfills all of the following * Disappearance of all detectable disease * LN\* \> 1.5 cm must decrease to ≤ 1.5 cm CRu: Fulfills all of the following * LN \>1.5 cm; SPD\*\* decrease \>75% * indeterminate bone marrow * LN: lymph nodes or nodal masses \*\* SPD: sum of the products of the greatest diameters

    Time frame: Up to 30 weeks

Secondary outcomes

  1. Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)

    The criteria for PR based on IWRC are shown below. PR: SPD regressed \> 50%

    Time frame: Up to 30 weeks

  2. Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)

    The criteria for CR based on the Revised RC are shown below. Definition: Disappearance of all evidence of disease Nodal Masses: 1. \[18F\]fluorodeoxyglucose (FDG)-avid or PET positive prior to therapy; mass of any size permitted if PET negative. 2. Variably FDG-avid or PET negative; regression to normal size on CT. Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.

    Time frame: Up to 30 weeks

  3. Overall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)

    The criteria for PR based on the Revised RC are shown below. Definition: Regression of measurable disease and no new sites Nodal Masses: 50% or more decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: 50% or more decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.

    Time frame: Up to 30 weeks

  4. Complete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979)

    The criteria for Complete response based on WHO Handbook for Reporting Results of Cancer Treatment (1979) are shown below. Measurable disease: The disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Unmeasurable disease: Complete disappearance of all known disease for at least 4 weeks. Bone metastases: Complete disappearance of all lesions on X-ray or scan for at least 4 weeks.

    Time frame: Up to 30 weeks

  5. Overall Response Rate (PR or Better) Based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)"

    The criteria for Overall response rate (PR or better) based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)" are shown below. Definition of PR: Measurable disease: 50% or more decrease in total tumor size of the lesions which have been measured to determine the effect of therapy by 2 observations not less than 4 weeks apart. In addition there can be no appearance of new lesions or progression of any lesion. Unmeasurable disease: Estimated decrease in tumor size of 50% or more for at least 4 weeks. Bone metastases: Partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for at least 4 weeks.

    Time frame: Up to 30 weeks

  6. Progression-Free Survival (PFS)

    PFS is the period from registration date to the earliest onset date of any progression event calculated using the Kaplan-Meier estimator. The median and the 95% confidence interval (CI) were calculated using Greenwood's formula. Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause. The date of progression was determined based on overall response assessed using IWRC, Revised RC, and WHO, and assessment by the primary physicians (excluding overall response).

    Time frame: Up to 30 weeks

  7. Duration of Response (DOR)

    DOR is the period from the date of achieving CR, CRu or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula. The date of achieving CR, CRu or PR was determined based on the overall response assessed using IWRC. The date of progression was determined based on overall response assessed using IWRC, Revised RC and WHO, and assessment by the primary physicians (excluding overall response). Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause.

    Time frame: Up to 30 weeks

  8. Overall Survival (OS)

    Death due to any given cause was defined as an event. OS was calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula.

    Time frame: Up to 30 weeks

  9. Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Discontinuation Due to Adverse Event

    Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.0, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA) Ver.16.1.

    Time frame: up to 30 weeks

  10. Laboratory Test Abnormalities (Biochemical Tests)

    Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE

    Time frame: up to 30 weeks

  11. Laboratory Test Abnormalities (Hematology Tests)

    Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE

    Time frame: up to 30 weeks

07

Results

Posted Apr 27, 2016

Participant flow

Participant flow — Overall Study
MilestoneLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell Lymphoma
Started6010
Completed429
Not completed181

Outcome measures

PrimaryComplete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)

The criteria for CR and CRu based on IWRC are shown below. CR: Fulfills all of the following * Disappearance of all detectable disease * LN\* \> 1.5 cm must decrease to ≤ 1.5 cm CRu: Fulfills all of the following * LN \>1.5 cm; SPD\*\* decrease \>75% * indeterminate bone marrow * LN: lymph nodes or nodal masses \*\* SPD: sum of the products of the greatest diameters

Time frame:
Up to 30 weeks
Reported as:
Number · percentage of participants
Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
percentage of participantsLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)67.870.068.1
SecondaryOverall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)

The criteria for PR based on IWRC are shown below. PR: SPD regressed \> 50%

Time frame:
Up to 30 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
percentage of participantsLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)96.690.095.7
SecondaryComplete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)

The criteria for CR based on the Revised RC are shown below. Definition: Disappearance of all evidence of disease Nodal Masses: 1. \[18F\]fluorodeoxyglucose (FDG)-avid or PET positive prior to therapy; mass of any size permitted if PET negative. 2. Variably FDG-avid or PET negative; regression to normal size on CT. Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.

Time frame:
Up to 30 weeks
Reported as:
Number · percentage of participants
Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)
percentage of participantsLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)64.480.066.7
SecondaryOverall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)

The criteria for PR based on the Revised RC are shown below. Definition: Regression of measurable disease and no new sites Nodal Masses: 50% or more decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: 50% or more decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.

Time frame:
Up to 30 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)
percentage of participantsLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Overall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)96.690.095.7
SecondaryComplete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979)

The criteria for Complete response based on WHO Handbook for Reporting Results of Cancer Treatment (1979) are shown below. Measurable disease: The disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Unmeasurable disease: Complete disappearance of all known disease for at least 4 weeks. Bone metastases: Complete disappearance of all lesions on X-ray or scan for at least 4 weeks.

Time frame:
Up to 30 weeks
Reported as:
Number · percentage of participants
Complete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979)
percentage of participantsLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Complete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979)22.040.024.6
SecondaryOverall Response Rate (PR or Better) Based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)"

The criteria for Overall response rate (PR or better) based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)" are shown below. Definition of PR: Measurable disease: 50% or more decrease in total tumor size of the lesions which have been measured to determine the effect of therapy by 2 observations not less than 4 weeks apart. In addition there can be no appearance of new lesions or progression of any lesion. Unmeasurable disease: Estimated decrease in tumor size of 50% or more for at least 4 weeks. Bone metastases: Partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for at least 4 weeks.

Time frame:
Up to 30 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (PR or Better) Based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)"
percentage of participantsLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Overall Response Rate (PR or Better) Based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)"86.490.087.0
SecondaryProgression-Free Survival (PFS)

PFS is the period from registration date to the earliest onset date of any progression event calculated using the Kaplan-Meier estimator. The median and the 95% confidence interval (CI) were calculated using Greenwood's formula. Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause. The date of progression was determined based on overall response assessed using IWRC, Revised RC, and WHO, and assessment by the primary physicians (excluding overall response).

Time frame:
Up to 30 weeks
Reported as:
Median · days
Progression-Free Survival (PFS)
daysLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Progression-Free Survival (PFS)NA (654.0 to NA)NA (NA to NA)NA (654.0 to NA)
SecondaryDuration of Response (DOR)

DOR is the period from the date of achieving CR, CRu or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula. The date of achieving CR, CRu or PR was determined based on the overall response assessed using IWRC. The date of progression was determined based on overall response assessed using IWRC, Revised RC and WHO, and assessment by the primary physicians (excluding overall response). Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause.

Time frame:
Up to 30 weeks
Reported as:
Median · days
Duration of Response (DOR)
daysLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Duration of Response (DOR)NA (541.0 to NA)NA (NA to NA)NA (541.0 to NA)
SecondaryOverall Survival (OS)

Death due to any given cause was defined as an event. OS was calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula.

Time frame:
Up to 30 weeks
Reported as:
Median · days
Overall Survival (OS)
daysLow-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Discontinuation Due to Adverse Event

Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.0, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA) Ver.16.1.

Time frame:
up to 30 weeks
Reported as:
Number · participants
Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Discontinuation Due to Adverse Event
participantsTotal
Any adverse event69
Adverse drug reaction69
SAE9
Death0
Discontinuation due to adverse events0
SecondaryLaboratory Test Abnormalities (Biochemical Tests)

Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE

Time frame:
up to 30 weeks
Reported as:
Number · participants
Laboratory Test Abnormalities (Biochemical Tests)
participantsTotal
Grade 3 : AST(GOT)3
Grade 3 : ALT(GPT)3
Grade 3 : γ-GTP1
Grade 4 : Uric acid1
Grade 3 : Na decrease1
Grade 3 : K decrease2
Grade 3 : K increase1
SecondaryLaboratory Test Abnormalities (Hematology Tests)

Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE

Time frame:
up to 30 weeks
Reported as:
Number · participants
Laboratory Test Abnormalities (Hematology Tests)
participantsTotal
Grade 3 : White blood cell count decreased45
Grade 4 : White blood cell count decreased12
Grade 3 : Neutrophil count decreased25
Grade 4 : Neutrophil count decreased34
Grade 3 : Lymphocyte count decreased6
Grade 4 : Lymphocyte count decreased63
Grade 3 : Haemoglobin decreased5
Grade 3 : Platelet count decreased3
Grade 4 : Platelet count decreased2

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SyB L-0501+Rituximab—9/69 (13%)69/69 (100%)
Most frequent serious events
Most frequent serious events
EventSyB L-0501+Rituximab
Febrile neutropeniaBlood and lymphatic system disorders3/69
tumour lysis syndromeMetabolism and nutrition disorders1/69
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/69
pneumonia cytomegaloviralInfections and infestations1/69
dermatitis allergicSkin and subcutaneous tissue disorders1/69
cytogenetic abnormalityCongenital, familial and genetic disorders1/69
atrial tachycardiaCardiac disorders1/69
pyrexiaGeneral disorders1/69
Most frequent other events
Showing 10 of 209
Most frequent other events
EventSyB L-0501+Rituximab
White blood cell count decreasedInvestigations69/69
Lymphocyte count decreasedInvestigations67/69
Neutrophil count decreasedInvestigations65/69
CD4 lymphocytes decreasedInvestigations64/69
NauseaGastrointestinal disorders46/69
ConstipationGastrointestinal disorders45/69
Platelet count decreasedInvestigations38/69
MalaiseGeneral disorders37/69
Blood immunoglobulin M decreasedInvestigations32/69
Decreased appetiteMetabolism and nutrition disorders30/69

Baseline characteristics

Of the 70 subjects enrolled, one who did not receive the investigational product was excluded. Therefore, the total number of Baseline Participants is 69.

Age, Customized
Age, Customized(participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
˂65 years36036
≥65 years231033
Sex: Female, Male
Sex: Female, Male(Participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Female37138
Male22931
Performance status (ECOG scale)
Performance status (ECOG scale)(participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
042749
116319
2101
Diagnosis (WHO classification)
Diagnosis (WHO classification)(participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
Small lymphocytic lymphoma202
Lymphoplasmacytic lymphoma202
Splenic marginal zone lymphoma000
B-EMZL(MALT lymphoma)404
Nodal marginal zone B-cell lymphoma000
Follicular lymphoma51051
Mantle cell lymphoma01010
Clinical stage (Ann Arbor staging classification)
Clinical stage (Ann Arbor staging classification)(participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
I - II15015
III909
IV351045
Number of lymph node regions
Number of lymph node regions(participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
0 region000
1 region12113
2 regions617
3 regions426
4 regions or more37643
Number of extranodal lesions
Number of extranodal lesions(participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
0 - 1 lesion50454
2 or more lesions9615
Tumor diameter (1)
Tumor diameter (1)(participants)Low-grade B-cell Non-Hodgkin's LymphomaMantle Cell LymphomaTotal
≥5 cm38442
˂5 cm21627

19 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • Research site
    Nagoya, Aichi, Japan
  • Research site
    Kashiwa, Chiba, Japan
  • Research site
    Sapporo, Hokkaido, Japan
  • Research site
    Isehara, Kanagawa, Japan
  • Research site
    Sendai, Miyagi, Japan
  • Research site
    Moriguchi, Osaka, Japan
  • Research site
    Izumo, Shimane, Japan
  • Research site
    Hamamatsu, Shizuoka, Japan
  • Research site
    Utsunomiya, Tochigi, Japan
  • Research site
    Fukuoka, Japan
  • Research site
    Kagoshima, Japan
  • Research site
    Kyoto, Japan
  • Research site
    Nagasaki, Japan
  • Research site
    Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2012
First posted
Oct 31, 2012
Start
Nov 2011
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Apr 27, 2016
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01718691
Responsible party
Sponsor
First posted
Oct 31, 2012
Start date
Nov 2011
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Apr 27, 2016
Last update
Apr 27, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Rituximab

Start the discussion